Printout from Pearl Cohen Zedek Latzer Baratz

News / Dec 13, 2017

Orgenesis And Pall Corporation Partnership Financed by the BIRD Foundation

Search By

  News & Publications

GERMANTOWN, Md., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Orgenesis Ltd., a wholly-owned subsidiary of Orgenesis Inc., (OTCQB:ORGSD) (“Orgenesis” or the “Company”), a vertically-integrated biopharmaceutical company with expertise and unique experience in gene and cell therapy and regenerative medicine, today announced that Orgenesis and Pall Corporation have completed their joint development program supported by the Israel-U.S. Binational Industrial Research and Development (“BIRD”) Foundation. Orgenesis is focused on developing an innovative autologous cell-based therapy for the treatment of diabetes.

Mark Cohen, Senior Partner and Chair of the Life Science Practice Group together with Yitzchak Chamudot, represented Orgenesis in its corporate matters in regard to the transaction.

Read these items